Ht-Logo-gigapixel-icon
Tuesday, December 10, 2024
Canada’s Politics and Government News Source Since 1989
Tuesday, December 10, 2024 | Latest Paper

Rob Henderson

Rob Henderson, president and CEO of BioTalent Canada, is a seasoned executive with more than 25 years of private and public sector management experience. He’s a member of the National Stakeholders Advisory Panel for the Labour Market Information Council.

Developing Canada’s vaccine infrastructure for future pandemics will depend on addressing bio-economy labour shortages

Opinion | BY ROB HENDERSON | September 13, 2021
The challenges of developing made-in-Canada vaccines may sound daunting, but Canada has done it before. We have a strong track record of innovation and vaccine development, including helping bring the polio vaccine to the world in the 1950s, writes Rob Henderson. Image courtesy of Pixabay
Opinion | BY ROB HENDERSON | September 13, 2021
Opinion | BY ROB HENDERSON | September 13, 2021
The challenges of developing made-in-Canada vaccines may sound daunting, but Canada has done it before. We have a strong track record of innovation and vaccine development, including helping bring the polio vaccine to the world in the 1950s, writes Rob Henderson. Image courtesy of Pixabay
Opinion | BY ROB HENDERSON | September 13, 2021
The challenges of developing made-in-Canada vaccines may sound daunting, but Canada has done it before. We have a strong track record of innovation and vaccine development, including helping bring the polio vaccine to the world in the 1950s, writes Rob Henderson. Image courtesy of Pixabay
Opinion | BY ROB HENDERSON | September 13, 2021
Opinion | BY ROB HENDERSON | September 13, 2021
The challenges of developing made-in-Canada vaccines may sound daunting, but Canada has done it before. We have a strong track record of innovation and vaccine development, including helping bring the polio vaccine to the world in the 1950s, writes Rob Henderson. Image courtesy of Pixabay